Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Iovance Biotherapeutics's Enterprise Value is €2,586.5 Mil.
Iovance Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-254.7 Mil. Therefore, Iovance Biotherapeutics's EV-to-FCF for today is -10.15.
The historical rank and industry rank for Iovance Biotherapeutics's EV-to-FCF or its related term are showing as below:
FRA:2LB'
s EV-to-FCF Range Over the Past 10 Years
Min: -10.67 Med: -4.09 Max: -0.66
Current: -10.07
During the past 13 years, the highest EV-to-FCF of Iovance Biotherapeutics was -0.66. The lowest was -10.67. And the median was -4.09.
FRA:2LB's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 17.815
vs FRA:2LB: -10.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Iovance Biotherapeutics's PE Ratio (TTM) for today is calculated as:
Iovance Biotherapeutics's share price for today is €5.65.
Iovance Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.626.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Iovance Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's EV-to-FCF falls into.
Iovance Biotherapeutics's current Enterprise Value is €2,586.5 Mil.
Iovance Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-254.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics (FRA:2LB) has a EV-to-FCF of -10.15 as of Aug. 13, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Iovance Biotherapeutics and its competitors. According to the industry distribution chart, Iovance Biotherapeutics ranks #999999 out of 332 companies in the Biotechnology industry.
Is Iovance Biotherapeutics' EV-to-FCF too high?
Iovance Biotherapeutics' current EV-to-FCF is -10.15. Based on the distribution chart, Iovance Biotherapeutics ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Iovance Biotherapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' EV-to-FCF compare to SLS and NUVB?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #999999 out of 332 companies for EV-to-FCF. This places Iovance Biotherapeutics in the lower half of its industry. The industry median EV-to-FCF is 17.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 17.82, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Iovance Biotherapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 17.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current EV-to-FCF is -10.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Iovance Biotherapeutics (FRA:2LB) has a current EV-to-FCF of -10.15. The current EV-to-FCF is -10.15. Iovance Biotherapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Iovance Biotherapeutics (FRA:2LB), the current EV-to-FCF is -10.15 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
34GF Score
Get the complete analysis for FRA:2LB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2LB has been successfully added to your 
